Proteomic prediction and Renin angiotensin aldosterone system inhibition prevention of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): Essential study design and rationale of a randomised clinical multicentre trial by Lindhardt, Morten et al.
Proteomic prediction and Renin
angiotensin aldosterone system
Inhibition prevention Of early diabetic
nephRopathy in TYpe 2 diabetic patients
with normoalbuminuria (PRIORITY):
essential study design and rationale of
a randomised clinical multicentre trial
Morten Lindhardt,1 Frederik Persson,1 Gemma Currie,2 Claudia Pontillo,3
Joachim Beige,4,5 Christian Delles,2 Heiko von der Leyen,6 Harald Mischak,3
Gerjan Navis,7 Marina Noutsou,8 Alberto Ortiz,9 Piero Luigi Ruggenenti,10
Ivan Rychlik,11 Goce Spasovski,12 Peter Rossing1,13
To cite: Lindhardt M,
Persson F, Currie G, et al.
Proteomic prediction and
Renin angiotensin aldosterone
system Inhibition prevention
Of early diabetic nephRopathy
in TYpe 2 diabetic patients
with normoalbuminuria
(PRIORITY): essential study
design and rationale of
a randomised clinical
multicentre trial. BMJ Open
2016;6:e010310.
doi:10.1136/bmjopen-2015-
010310
▸ Prepublication history and
additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/bmjopen-2015-
010310).
Received 22 October 2015
Revised 15 January 2016
Accepted 21 January 2016
For numbered affiliations see
end of article.
Correspondence to
Dr Morten Lindhardt;
Mkfl@steno.dk
ABSTRACT
Introduction: Diabetes mellitus affects 9% of the
European population and accounts for 15% of
healthcare expenditure, in particular, due to excess
costs related to complications. Clinical trials aiming for
earlier prevention of diabetic nephropathy by renin
angiotensin system blocking treatment in
normoalbumuric patients have given mixed results.
This might reflect that the large fraction of
normoalbuminuric patients are not at risk of
progression, thereby reducing power in previous
studies. A specific risk classifier based on urinary
proteomics (chronic kidney disease (CKD)273) has
been shown to identify normoalbuminuric diabetic
patients who later progressed to overt kidney disease,
and may hold the potential for selection of high-risk
patients for early intervention. Combining the ability of
CKD273 to identify patients at highest risk of
progression with prescription of preventive aldosterone
blockade only to this high-risk population will increase
power. We aim to confirm performance of CKD273 in a
prospective multicentre clinical trial and test the ability
of spironolactone to delay progression of early diabetic
nephropathy.
Methods and analysis: Investigator-initiated,
prospective multicentre clinical trial, with randomised
double-masked placebo-controlled intervention and a
prospective observational study. We aim to include
3280 type 2 diabetic participants with
normoalbuminuria. The CKD273 classifier will be
assessed in all participants. Participants with high-risk
pattern are randomised to treatment with
spironolactone 25 mg once daily, or placebo, whereas,
those with low-risk pattern will be observed without
intervention other than standard of care. Treatment or
observational period is 3 years.
The primary endpoint is development of confirmed
microalbuminuria in 2 of 3 first morning voids urine
samples.
Ethics and dissemination: The study will be
conducted under International Conference on
Harmonisation – Good clinical practice (ICH-GCP)
requirements, ethical principles of Declaration of Helsinki
and national laws. This first new biomarker-directed
intervention trial aiming at primary prevention of diabetic
nephropathy may pave the way for personalised medicine
approaches in treatment of diabetes complications.
Trial registration number: NCT02040441; Pre-
results.
INTRODUCTION
Diabetic nephropathy (DN), characterised by
declining renal function and increasing albu-
minuria (>300 mg/day), is the leading cause
Strengths and limitations of this study
▪ Multinational, multicentre investigator-initiated
clinical trial.
▪ Aim to include more than 3000 participants with
3 years follow-up.
▪ Randomised, double masked intervention with
spironolactone 25 mg, or placebo, in selected
participants.
▪ Biomarker-directed therapy trial aiming at
primary prevention of diabetic nephropathy.
▪ Validation of pre-existing urinary proteomics-
based chronic kidney disease (CKD) risk classi-
fier (CKD273).
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of end-stage renal disease (ESRD) in the Western world,
and is associated with signiﬁcant cardiovascular morbid-
ity and mortality.1 Microalbuminuria (>30 mg/g) is the
earliest and most commonly used clinical hallmark of
increased risk for DN and has evolved into a key marker
for risk prediction and treatment monitoring in diabetes.
Despite this, numerous alternative biomarkers have been
proposed for early identiﬁcation of individuals at risk of
progression to DN, as the sensitivity and speciﬁcity of
microalbuminuria for early detection of disease are
limited by a number of factors: high day-to-day variability
of urine albumin excretion; the phenomenon of non-
albuminuric DN;2 3 and presence of advanced renal
pathological changes by the time microalbuminuria is
clinically detectable,4 but to date, none have outper-
formed microalbuminuria in large-scale, prospective
studies. For optimal and early diagnosis of individuals at
risk of DN, and thereby a need for aggressive interven-
tion, there is a requirement for new markers that can be
used in addition to urinary albumin excretion and renal
function (glomerular ﬁltration rate; GFR). The patho-
genesis of DN is complex and incompletely understood,
meaning that it may be simplistic to expect that a single
biomarker could perform adequately for early disease
detection, risk assessment and therapeutic monitoring.
Chronic kidney disease (CKD)273 is a proteomic panel
of 273 urinary peptides which has been validated for
diagnosis of DN in a multicentre setting, and shows
promise as a tool for detection of DN years before devel-
opment of microalbuminuria.5–7
The renin-angiotensin-aldosterone system (RAAS)
plays a key role in the development and progression of
DN, and its blockade with ACE-inhibitors (ACEI) or
angiotensin II receptor blockers (ARB) is considered
ﬁrst-line therapy for renoprotection in diabetes.8–10
Studies of early initiation of RAAS blockade have shown
delay in onset of microalbuminuria, at the cost of
increased side-effect burden and cardiovascular events.11
To date, these studies have been performed in largely
unselected populations, and their limited success may
reﬂect the fact that fewer patients progress to DN than
previously thought, reducing the power.12 13
Recent years have seen a resurgence of interest in the
role of aldosterone as a mediator of atherosclerotic
disease, endothelial dysfunction and oxidative stress.
Furthermore, ‘aldosterone breakthrough’ has been asso-
ciated with a more rapid decline in renal function in
patients with DN.14 Numerous small studies suggest that
addition of aldosterone antagonist to ACEI or ARB may
reduce albuminuria in patients with CKD although
large, long-term studies of this therapeutic strategy are
lacking.15 It seems feasible that targeting appropriately
intensiﬁed early preventative therapy towards those at
highest risk could limit disease progression as well as
side effects resulting from unnecessary prescribing.
To make the transition from bench to bedside, bio-
markers must be shown to outperform the current
state-of-the-art in large-scale studies, and to inform
therapeutic decision-making. The PRIORITY study
(proteomic prediction and renin angiotensin aldoster-
one system inhibition prevention of early DN in type 2
diabetic patients with normoalbuminuria),16 therefore,
aims to address two clinical questions: ﬁrst to conﬁrm
that CKD273 can predict development of microalbumi-
nuria in a large cohort of normoalbuminuric patients
with type 2 diabetes; and second to determine whether
early initiation of aldosterone antagonism can reduce
risk of transition to microalbuminuria in individuals
identiﬁed as ‘high risk’ participants.
METHODS AND ANALYSIS
Study population
The study includes type 2 diabetic patients with preserved
kidney function (estimated GFR (eGFR)>45 mL/min/
1.73 m2) and normoalbuminuria (urine albumin to cre-
atinine ratio (UACR)<30 mg/g in two of three consecutive
morning urine samples). Participants who are eligible,
according to the inclusion and exclusion criteria at the
screening visit, can be included in the trial (table 1).
Study design
Prospective observational study of participants were
stratiﬁed as high or low risk based on CKD273, and a
prospective, multicentre, randomised, double-masked,
placebo-controlled trial of spironolactone in the high-
risk patients. All participants fulﬁlling the inclusion cri-
teria will be screened with CKD273 classiﬁer in order to
determine the risk of future DN (ﬁgure 1).
Participants with a high-risk pattern will be included
in the randomised intervention study with active drug or
placebo in addition to standard care, whereas partici-
pants with a low-risk pattern will be followed-up on
standard-of-care without speciﬁc intervention as part of
the trial. All participants will be followed for 3 years after
the baseline visit.
Intervention
In addition to standard diabetes care, participants with a
high-risk proteomics pattern will be randomised to receive
the study drug: spironolactone 25 mg tablets for oral use
once daily or matching placebo. The randomisation
process is computer generated, and randomisation lists
will be prepared by an independent statistician at the
Robertson Institute, University of Glasgow. The study drug
will be labelled with a unique pack identiﬁer number.
Assignment to study medication is provided by email to
the investigators though a web-based system. Participants
will be stratiﬁed based on whether or not they are treated
with RAAS blocking agents at baseline. Randomisation will
be performed 1:1 for placebo and active drug.
Both the study personnel and the patient will be
masked to the type of intervention. Placebo and active
study drug will not be distinguishable from each other
in terms of appearance, odour, labelling or instructions
for use. The masking of treatment allocation will be
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Table 1 Inclusion and exclusion criteria
Inclusion criteria 1. Written informed consent must be provided before participation. Patient information and consent form
must be approved by relevant IEC. Specifically, all participating patients will be asked to give
informed consent for long-term follow-up
2. Male or female with age ≥18 years and <75 years
3. Diagnosed with type 2 DM (WHO criteria)
4. Persistent normoalbuminuria (at least 2 of 3 UACR <30 mg/g samples from ‘run in’-period)
5. eGFR >45 mL/min/1.73 m2 at screening visit
6. HbA1c ≥6.5% (48 mmol/mol) and <13% (119 mmol/mol) at screening visit
7. The patient must be willing and able to comply with the protocol for the duration of the study
8. Female without childbearing potential at the screening visit. Defined as one or more of following:
8.1 Female patients ≥50 years of age on the day of inclusion, who have been postmenopausal for at
least 1 year
8.2 Female patients <50 years of age at the day of inclusion, who have been postmenopausal for at
least 1 year and serum FSH levels >40 mIU/mL as well as serum oestrogen levels <30 pg/mL or
a negative oestrogen test
8.3 6 weeks after surgical sterilisation by bilateral tubal ligation or bilateral ovariectomy with or
without hysterectomy
OR a negative urine pregnancy test at the screening visit AND one or more of following:
8.4 Correct use of reliable contraception methods. This includes one or more of the following:
hormonal contraceptive (such as injection, transdermal patch, implant, cervical ring or oral) or an
intrauterine device OR correct use of double barrier with one of the following: barrier methods
(diaphragm, cervical cap, Lea contraceptive, femidom or condom) AND in combination with a
spermicide
8.5 General sexual abstinence from the time of screening/during the study until a minimum of
30 days after the last administration of study medication if this is already established as the
patient’s preferred and usual lifestyle
8.6 Having only female sexual partners
8.7 Sexual relationship with sterile male partners only
Exclusion criteria 1. Average of systolic BP <110 or >160 mm Hg at baseline
2. Average of diastolic BP >100 mm Hg at baseline
3. Type 1 DM (WHO criteria)
4. Current in treatment with more than one RAAS blocking agent (ACEI, ARB or direct renin inhibitor)
5. Current lithium treatment.
6. Known or suspected hypersensitivity to spironolactone or to any of its excipients.
7. Current use of potassium sparing diuretics, such as: spironolactone, eplerenone or amiloride etc
8. Screening (week-6) plasma (or serum) potassium level >5.0 mmol/L
9. Hypernatraemia determine by the investigator
10. Current cancer treatment or within 5 years from baseline (except basal cell skin cancer or
squamous cell skin cancer)
11. Any clinically significant disorder, except for conditions associated with type 2 DM history, which in
the Investigators opinion could interfere with the results of the trial.
12. Cardiac disease defined as: heart failure (NYHA class III–IV) and/or diagnosis of unstable angina
pectoris and/or MI, stroke, PTCA or CABG within the last 3 months.
13. Body mass index <18.5 or >40 kg/m2
14. Diagnosis of non-diabetic CKD current or in the past
15. Diagnosis of liver cirrhosis with current impaired liver function within the last 3 years
16. Diagnosis of Addison’s disease
17. Being lactating
18. Intend to become pregnant within the duration of the study or not use adequate birth control
19. Known or suspected abuse of alcohol or narcotics
20. Not able to understand informed consent form
21. Participation in any other intervention trial than PRIORITY or a related substudy is not allowed
within 30 days before inclusion or concurrent to this study
ACEI, ACE-inhibitors; ARB, angiotensin II receptor blockers; BP, blood pressure; CABG, coronary artery bypass grafting; CKD, chronic kidney
disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; FSH, follicle-stimulating hormone; HbA1c, glycated haemoglobin;
IEC, independent ethics committee; NYHA, New York Heart Association; PRIORITY, proteomic prediction and renin angiotensin aldosterone
system inhibition prevention of early DN in type 2 diabetic patients with normoalbuminuria; PTCA, percutaneous transluminal coronary
angioplasty; RAAS, renin-angiotensin-aldosterone system; UACR, urine albumin to creatinine ratio.
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maintained until data lock. The study drug will be pro-
duced, stored and distributed in accordance with good
manufacturing practice and good distribution practice.
Study visits
At the screening visit, local laboratory blood samples will be
taken for creatinine, sodium, potassium and glycated
haemoglobin (HbA1c). Compliance with inclusion and
exclusion criteria will be evaluated. Weigh, height, blood
pressure and heart rate will be measured. Urine sample for
proteomic risk assessment with CKD273 will be obtained.
Urine samples from the ‘run-in-phase’ will be collected
3 days following the screening visit and brought or sent to
the study site. The baseline visit will be performed 6 weeks
after the screening visit.
Participants with a high-risk proteomics pattern will be
provided with study medication after randomisation, and
seen for a safety visit at the study centre after 2 weeks,
with local measurement of creatinine and potassium.
Every 13th week, participants will be seen in the clinic
and provided with the study drug. At each visit, partici-
pants will be tested for UACR in three consecutive urine
samples, and locally measured biochemistry.
Participants with a low-risk CKD273 pattern will be
seen once yearly after the baseline visit and tested for
UACR in three consecutive urine samples as well as
locally measured biochemistry.
Morning void urine samples are collected by the parti-
cipants at home on three consecutive days, and brought
or sent to the study centre. Participants are provided
with a written instruction on how to collect urine
samples. Samples are tested for urinary tract infection
and in case of urinary tract infection samples are
re-done after relevant medical treatment.
Concomitant medical treatment
Treatment of any medical condition aside from hyper-
tension, albuminuria and hyperkalaemia must be in
accordance with local guidelines. If local guidelines do
not recommend a speciﬁc ﬁrst-line antihypertensive
agent it is suggested to start with a calcium channel
blocker, or thiazide diuretic, to reduce interference with
UACR. Antihypertensive treatment prior to inclusion,
especially ACEI or ARB treatment, should be continued
unchanged during the ‘run-in phase’ and throughout
the study if possible. Participants not on treatment with
ACEI or ARB at the time of screening should not start
such treatment before the primary endpoint is reached,
however, it is not prohibited if indicated due to high
blood pressure, although a calcium channel blocker or
thiazide diuretics is recommended as ﬁrst-line interven-
tion unless local guidelines necessitate other interven-
tion. In the duration of the trial, conﬁrmed blood
pressure >140 mm Hg systolic and or diastolic
>90 mm Hg is considered hypertension where treatment
must be considered.
Plasma or serum level of potassium >0.4 mmol/L
above local upper reference range is considered hyper-
kalaemia. The study protocol contains speciﬁc treatment
guidelines to be followed in case of hyperkalaemia (see
online supplementary material). In brief: (1) conﬁrm
potassium concentration in a non-haemolysed sample,
(2) advise lower dietary intake, (3) review medical treat-
ment for agents known to cause hyperkalaemia, (4) con-
sider treatment with non-potassium sparing diuretics.
Temporarily pausing or discontinuation of study medica-
tion is mandatory in cases of potassium >0.9 mmol/L
above local upper reference range.
For low-risk patients, routine diabetes treatment can
be performed by healthcare providers who are not part
of the study team.
Primary endpoint
Development of conﬁrmed microalbuminuria
(UACR>30 mg/g) in at least two of three ﬁrst morning
voids with a 30% increase (geometric mean) in UACR
from ‘run-in-phase’ samples, or >40 mg/g (geometric
mean).
The primary end point is measured at the central
laboratory at Steno Diabetes Center on a continuous
basis as the trial is running. After arrival and defrosting,
the samples are spun for 10 min at 1680 g before subse-
quent analysis of urine creatinine and urine albumin
(Vitros 5600, Ortho C. Diagnostics, France).
In addition to the primary end point, the study proto-
col prespeciﬁes other renal and cardiovascular second-
ary end points including change in eGFR (see online
supplementary material). To address future scientiﬁc
questions, blood, urine and DNA samples will be col-
lected at time of randomisation and at end of study.
Sample preparation for urinary proteomics
A total of 0.7 mL of urine will be diluted with 0.7 mL,
2 mol/L urea and 10 mmol/L NH4OH containing
0.02% SDS. For removal of high-molecular weight poly-
peptides, samples will be ﬁltered using Centrisart
Figure 1 Study design. DM, diabetes mellitus.
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ultracentrifugation ﬁlter devices (20 kDa molecular
weight cut-off; Sartorius, Göttingen, Germany)
Subsequently, the ﬁltrate will be desalted using a PD-10
column (GE Healthcare, Stockholm, Sweden) equili-
brated in 0.01% NH4OH in high-performance liquid
chromatography-grade water. Finally, samples will be lyo-
philised and stored at 4°C. Shortly before capillary elec-
trophoresis mass spectrometric (CE-MS) analysis,
lyophilisates will be resuspended in high-performance
liquid chromatography-grade water to a ﬁnal protein con-
centration of 0.8 mg/mL checked by BCA assay
(Interchim, Montlucon, France). CE-MS analysis will be
performed with a P/ACE MDQ capillary electrophoresis
system (Beckman Coulter, USA) coupled to a
micro-TOF-MS (Bruker Daltonic, Germany). Technical
details and characteristics of the CE-MS platform were
extensively described recently.17
Urinary proteomic analysis and data processing
CE-MS analysis results in individual data sets contain
information on generally 1200–2000 peptides per
sample. Mass spectral ion peaks representing identical
molecules at different charge states (m/z with z=1, 2,
3…) will be deconvoluted into single masses using
MosaiquesVisu software, which employs a probabilistic
clustering algorithm and uses isotopic distribution (for
z≤6), as well as conjugated masses for charge-state deter-
mination of peptides/proteins.18 For noise ﬁltering,
signals with z>1 observed in a minimum of three consecu-
tive spectra, with a signal-to-noise ratio of at least four will
be considered. For clustering, peptides in different
samples will be considered identical, if the mass deviation
is lower than ±50 ppm for 800 Da peptides, gradually
increasing to ±75 ppm for 15 kDa peptides. Data sets will
be accepted only if the following quality control criteria
are met: A minimum of 800 peptides (500 peptides on
the Q-TOF) must be detected with a minimal MS reso-
lution of 8.000 (required resolution to resolve ion signals
with z=6) in a minimal migration time interval (the time
window in which separated signals can be detected) of
10 min. All detected polypeptides will be deposited,
matched and annotated in a Microsoft Structured Query
Language database.19 The ﬁnal result is a peak list, char-
acterising each protein and peptide by its molecular mass
(Da), and normalised CE migration time (min).
Migration time and ion signal intensity (amplitude) will
be normalised using internal polypeptide standards that
include 29 collagen fragments that are generally found in
urine, and that do not appear to be highly signiﬁcantly
associated with disease.20
Proteomics classification
The CKD273 classiﬁer is a Support Vector Machine
(SVM)-based classiﬁcation model21 22 that was developed
for discrimination between patients with CKD and con-
trols.23 Classiﬁcation is performed by determining the
Euclidian distance (deﬁned as the SVM classiﬁcation
score) of the 273-dimensional vector to a
272-dimensional maximal margin hyperplane.23 In previ-
ous studies, CKD273 threshold of 0.343 was found to dis-
criminate between patients with and without DN.24 To
accommodate the early detection of CKD, the cut-off for
use in PRIORITY trial was lowered from 0.343 to 0.154.
This decision was based on a post hoc analysis of 737
type 2 diabetic patients from the DIRECT-2 study, where
this cut-off was associated with increased risk of progres-
sion to microalbuminuria independent of eGFR and
UACR, and was present in 20% of the participants.25
Scoring above this threshold indicates high risk of devel-
opment of DN.
Statistical analysis
A statistical analysis plan (SAP) will be written and
signed before database lock. Analyses not described
here or in the SAP will be considered exploratory/post
hoc analyses.
The predictive value of a positive and negative test,
speciﬁcity and sensitivity of the test in relation to predic-
tion of development of the primary end point will be
calculated. To assess whether CKD273 improves risk pre-
diction of the primary outcome we will determine the
concordance statistic (c-statistic). Both parameters
measure the discriminative ability of a marker in a
model to distinguish between people who will or will not
develop the outcome (in case of predictive methods).
The primary end point will be analysed in the total
population with comparisons of high-risk versus low-risk
pattern and active versus placebo treatment using a Cox
proportional-hazards regression model with treatment as a
ﬁxed effect. The model will be adjusted for independent
predictive covariates and at least for the baseline UACR. A
two-tailed Wald χ2 test with an α level of less than 0.05, and
HRs with two-sided 95% CIs will be calculated.
The study statistician will be partly unmasked while
conducting statistical analysis with information regarding
an ad hoc allocation to either group 1 or 2, but without
information about which group received active or
placebo treatment. Final unmasking will be done after
all analysis in the SAP has been conducted.
Sample size
The expected relative proportions of type 2 diabetic
patients developing microalbuminuria (within 3 years)
in our study population are: 25% in participants at high
risk for DN in the treatment group, 35% in participants
at high risk for DN in the placebo group, and 4% in
therapy-naive participants at low risk for DN. Using the
samples size formula for two proportions test (α=0.05
β=0.80), randomised (1:1), n=328 in each arm of the
intervention group is required. It is expected that
approximately 20% of the population will be at high risk
based on CKD273, therefore, at least 3280 participants
have to be included overall.
Estimated sample size can be revisited in an amend-
ment to the study protocol if new data emerge while
conducting the trial.
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ETHICS AND DISSEMINATION
The study will be performed under International
Conference on Harmonisation – Good clinical practice
(ICH-GCP) requirements, ethical principles of the
Declaration of Helsinki, and national laws and regula-
tions depending on each country. Written favourable
opinion from independent ethical committees must be
obtained before starting the study in the respective
country. The study is a prospective study, and written
approval of the respective national competent author-
ities and/or other regulatory authorities, if applicable,
must be available before study-speciﬁc procedures are
performed for the ﬁrst participant.
It is the responsibility of the investigator to obtain
written informed consent from each individual partici-
pating in this study after adequate explanation of the
aims, methods, objectives and potential hazards of the
study. It should be made clear that refusal to participate
or withdrawal from the trial at any stage will have no
consequences regarding the patient’s subsequent care.
No patient should feel obliged to participate in the trial.
If there is any doubt as to whether the patient has
understood the written and verbal information, the
patient should not enter the trial.
Data from the study will be published in international,
peer-reviewed journals.
Project management
The chief investigator is professor Peter Rossing. The
consortium consists of 15 partners from 10 countries,
with 13 study centres including participants. The trial is
registered at the EU Clinical Trials Register (EudraCT:
2012-000452-34), as well as at http://www.clinicaltrial.
gov (NCT02040441). An external advisory board con-
tributed in the creation of the study protocol. Prior to
inclusion of participants, an independent data monitor-
ing committee will be established.
DISCUSSION
The PRIORITY study is innovative in several ways and
will provide important data, regardless of its outcome.
First, the prospective validation of a new biomarker in a
chronic disease such as diabetes, is unique, and will
provide solid answers instead of speculations so fre-
quently put forward from retrospective biomarker
studies. Second, this investigator-initiated multicentre
study will investigate the effect of spironolactone, an off-
patent drug with the potential to provide early preven-
tion of DN, by contrast with new and more expensive
drugs with a less robust clinical safety record.
Combining the ability to select high-risk individuals
based on a new biomarker, and a clinical trial with inter-
vention, thus provides information both on the utility of
the biomarker, as well as the effect of the intervention,
for the targeted high-risk population. Third, the
PRIORITY study represents a remarkable clinical collab-
oration across Europe, with the support of the EU, and
as such, experiences from the study may provide a blue-
print for future non-industry-led clinical trials in indica-
tions and diseases currently not covered by available
evidence.
Several markers have been suggested as predictors of
DN, in particular, elevated the urinary albumin excre-
tion rate.26 Urinary albumin has, however, turned out to
be less speciﬁc than originally thought, and thus,
markers that can improve precision in prediction as well
as provide even earlier indications on increased risk for
DN are warranted.
The present study will validate a new test based on
urinary proteomics in a prospective way. Whereas micro-
albuminuria is thought to reﬂect the presence of glom-
erular ﬁltration barrier damage with increased leak of
albumin into the urine, we propose that the urinary
proteomic-based classiﬁer (CKD273) reﬂects altered
composition of mesangial extracellular matrix compo-
nents, which occur before any structural damage to the
ﬁltration barrier has developed. In fact, we have demon-
strated that changes in the urinary peptidome can
predict the development of overt DN in patients with
normoalbuminuria.7 23 24 The urinary proteomic
marker not only differentiates between normoalbumi-
nuria and DN, but also identiﬁes participants at risk of
progression from normoalbuminuria to macroalbumi-
nuria, about 4 years before development of DN.7 This
proteomic test has been evaluated in cross-sectional and
retrospective longitudinal studies but, not unlike other
biomarkers, it has not yet been investigated in speciﬁc-
ally designed prospective studies.
Blockade of the renin angiotensin system with ACEI
or ARB has been the cornerstone of renoprotective
treatment in diabetes. RAAS blockade is best established
in patients with microalbuminuria or macroalbumi-
nuria,8 27 whereas, early treatment/prevention in nor-
moalbuminuric patients has yielded more variable
results.11 28 29 In recent years, it has become clear that
aldosterone should be considered a hormone with wide-
spread unfavourable effects on the vasculature, the heart
and the kidneys.30–32 We have demonstrated that ele-
vated plasma aldosterone despite long-term treatment
with losartan, what has been termed ‘aldosterone break-
through’, is associated with a faster decline of GFR in
type 1 diabetic patients with DN.14 Short-term studies in
proteinuric type 1 and type 2 diabetic patients have
demonstrated that spironolactone safely adds to the
renal and cardiovascular protective beneﬁts of treatment
with maximally recommended doses of ACEI or ARB by
reducing albuminuria and blood pressure.33 34 The
selective aldosterone receptor antagonist, eplerenone,
also reduced proteinuria by 48% when added to an
ACEI in type 2 diabetes patients with albuminuria
>50 mg/g.35 In less advanced DN (microalbuminuria),
we observed an even larger effect on urinary albumin
excretion when adding spironolactone to standard treat-
ment including an ACEI, with reductions of 60% in
albuminuria, suggesting that early prevention is better
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than treatment.36 Although treatment with aldosterone
blockade has been avoided for many years in nephrol-
ogy, participants eligible for this trial will not suffer from
renal impairment, and the dose of spironolactone is low,
thus, the risk of adverse events due to hyperkalaemia or
gynaecomastia is reduced.
The PRIORITY study population consists of patients
with type 2 diabetes, which is highly relevant, as preva-
lence and incidence of this chronic condition are increas-
ing in Europe and worldwide.37 Currently, type 2 diabetes
accounts for 15% of the healthcare budget in European
nations, and prevention or delaying of complications
such as DN is vital in order to prevent health costs from
increasing. A patient with complications costs approxi-
mately six times more than a patient with uncomplicated
type 2 diabetes.38 In addition, patients with DN are at risk
of substantial comorbidity, as well as cardiovascular com-
plications and advanced kidney disease. Diabetes repre-
sents the leading cause of ESRD in most of the world.
Any early intervention that can prevent or delay DN will,
therefore, have substantial impact. A health economic
cost-beneﬁt analysis should be performed after publica-
tion of results from the PRIORITY trial to compare costs
related to screening with new markers and early treat-
ment versus potentially saved costs on prevented ESRD
treatment and ESRD complications.
LIMITATIONS OF THIS STUDY
The major limitation of this study is that our primary
end point is only a surrogate end point (development of
microalbuminuria) rather than a hard end point, such
as doubling of serum creatinine, development of ESRD
or renal death, but so far, development of microalbumi-
nuria is the only available end point for early interven-
tion. This surrogate end point was chosen instead of
using hard end points, as the trial is conducted in a nor-
moalbuminuric population. Development of hard renal
end points can take up to 20 years12 in such populations,
hence, persistent microalbuminuria, which is considered
a valid surrogate end point will be a feasible and accept-
able outcome for our study.39 The aim to replace albu-
minuria as a biomarker, by designing a study based on
albuminuria as outcome, may appear suboptimal at ﬁrst
glance. However, despite all criticisms, microalbuminuria
has consistently found its way into clinical guidelines
and is the key event in a diabetes patient’s clinical
course that triggers the initiation of renoprotective
therapy. As such, the prediction and prevention of
microalbuminuria, despite its limitations, is a clinically
important surrogate end point that has changed clinical
practice.40
With assignment of treatment to the participants with
a high-risk pattern only, the trial cannot address the
effect of treatment in participants with a low-risk pattern
or answer the question of whether the combination of
screening and treatment is superior to a non-screening.
There is no wash-out period included at the end of
the study. Thus, we cannot exclude that UACR would
increase to microalbuminuric levels in the intervention
group if treatment was withdrawn. On the other hand,
several studies have demonstrated that reduction in
UACR with treatment predicts decreased development
of renal and cardiovascular end points.41 42
Future translation of the results of this trial into wide-
spread clinical practice will be challenging due to the
cost and complexity of the proteome analysis and asso-
ciated intellectual property rights. Currently, only a
limited number of laboratories worldwide are able to
perform the CE-MS analysis to the required standard,
and to analyse the MS data to produce the CKD273 clas-
siﬁer. The limited number of diagnostic laboratories is
in contrast with the potential need in the event that the
CKD273 classiﬁer delivers its promises. However, CE-MS
technology itself is widely available, and speciﬁc analysis
pipelines can be applied based on the patent holder’s
protocols and, thereby, widely implemented across
laboratories worldwide. Alternatively, multiplex markers
may be developed, but the sensitivity and speciﬁcity will
be reduced if the number of peptides included in the
classiﬁer is reduced.
POTENTIAL IMPACT OF THE PRIORITY TRIAL
Previous and current trials usually aim to include partici-
pants with a speciﬁc phenotype based on biochemical
values such as eGFR and/or level of albuminuria. By
contrast, our novel approach uses targeted intervention
based on a proteomics-based risk classiﬁer. This will be
the ﬁrst ‘omics’-based biomarker-directed therapy trial
targeting type 2 diabetes patients, aiming at primary pre-
vention of DN. Furthermore, as the urinary proteomic
test is based on a large number of polypeptides related
to different processes associated with progression of
renal disease, improved understanding of these pro-
cesses could further improve the possibilities for perso-
nalised medicine as well as new targeted interventions.
If the proteomic classiﬁer is validated in this prospect-
ive study, we will establish an earlier marker for DN than
microalbuminuria, and potentially, a much more speciﬁc
one. This will enable us in future studies to include only
high-risk patients in interventional trials, increasing the
event rate and reducing the number of patients needed
to be included in the trial. Furthermore, identiﬁcation
of low-risk patients who do not need additional renopro-
tective treatment will protect them from unnecessary
intervention, risk of side effects and save medical costs.
Even if we are not successful with both our aims, we
may still prove the value of the biomarker, or the beneﬁt
of early intervention with spironolactone. However, if
the study successfully achieves both aims, we will have a
new diagnostic strategy for early identiﬁcation of indivi-
duals at risk for the most devastating and expensive com-
plication of diabetes, as well as a cheap intervention to
offer.
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